Figure 2.

αTIGIT and bintrafusp alfa combination therapy provides significant antitumor activity, increases survival, and provides immunologic memory. (a) Graphical representation of experimental design for MC38-CEA tumor studies. (b) MC38-CEA tumor growth curves and (c) survival proportions of CEA.Tg mice treated with αTIGIT (red line; n = 10), bintrafusp alfa (blue line; n = 10), αTIGIT + bintrafusp alfa (purple line; n = 10) or untreated controls (black line; n = 10). Numbers in parentheses indicate median overall survival in days. Tumor-free mice (red line; n = 7) from (c) were rechallenged with MC38-CEA cells and monitored for (d) tumor progression and (e) overall survival in comparison to naïve mice (black line; n = 10).